2015
DOI: 10.1016/j.pcd.2014.03.007
|View full text |Cite
|
Sign up to set email alerts
|

Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

13
103
0
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 117 publications
(117 citation statements)
references
References 6 publications
13
103
0
1
Order By: Relevance
“…We observed that the mean of lipid pro le abnormality associated with "high/low tendency to progress diabetes" states. This nding is in line with the results of previous studies have emphasized on the association of lipid pro le disorders with the risk of diabetes (11,12,23,(33)(34)(35)(36).…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…We observed that the mean of lipid pro le abnormality associated with "high/low tendency to progress diabetes" states. This nding is in line with the results of previous studies have emphasized on the association of lipid pro le disorders with the risk of diabetes (11,12,23,(33)(34)(35)(36).…”
Section: Discussionsupporting
confidence: 92%
“…Previous evidences suggested that lipid abnormalities are common in people with T2DM and PD (10,11). For instance, a meta-analytic review demonstrated that lipid pro le disorders signi cantly associated with T2DM (12). A community based cross-sectional survey showed a strong association between serum lipid pro le with T2DM and PD (13).…”
Section: Introductionmentioning
confidence: 99%
“…We also used the AIP that is considered as a very sensitive predictor of future cardiovascular events and that is defined as log(triglycerides/HDL cholesterol) .…”
Section: Methodssupporting
confidence: 87%
“…Although statin therapy reduces elevated LDL cholesterol with clinically significant reductions in all forms of CVD, to date, attempts to find a safe and effective pharmacological agent to raise low HDL levels which lead to favorable clinical outcomes have not been very successful (17). In the absence of a safe and effective pharmacotherapy to optimize atherogenic dyslipidemia, clinical guidelines emphasize the importance of non-pharmacological interventions to achieve favorable HDL cholesterol (15).…”
Section: Discussionmentioning
confidence: 99%